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Abstract
Gastric cancer is the second leading cause of cancer-
related deaths worldwide. Conventional cytotoxic che-
motherapy has limited efficacy for metastatic gastric 
cancer, with an overall survival of approximately ten 
months. Recent advances in high-throughput technolo-
gies have enabled the implementation of personalized 
cancer therapy for high-risk patients. The use of such 
high-throughput technologies, including microarray 
and next generation sequencing, have promoted the 
discovery of novel targets that offer new treatment 
strategies for patients lacking other therapeutic op-
tions. Many molecular pathways are currently under 
investigation as therapeutic targets in gastric cancer, 
including those related to the epidermal growth factor 
receptor family, the mesenchymal-epithelial transition 
factor axis, and the phosphatidylinositol 3-kinase-AKT-
mammalian target of rapamycin factors. Advances in 
molecular diagnostic tools further support the discovery 
of new molecular targets. Limitations exist, however; 
not all patients can be tested for biomarkers, and nu-
merous challenges hamper implementation of targeted 
therapy in clinical settings. Indeed, the scale of tumor 
genomic profiling is rapidly outpacing our ability to ap-
propriately synthesize all the information in order to 
optimally refine patient care. Therefore, clinicians must 
continue to educate themselves regarding new tools 
and frameworks, and to utilize multidisciplinary team 
science, comprised of oncologists, geneticists, patholo-
gists, biologists and bioinformaticians, to successfully 
implement this genomic approach therapeutically.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Understanding the molecular mechanisms 
governing carcinogenesis, progression and prognosis 
of gastric cancer is a prerequisite for development of 
effective management strategies. Analysis of genomic 
and proteomic expression profiles of oncogenic sig-
naling pathways have revealed different molecular 
subtypes of gastric cancer. Development of personal-
ized cancer therapy regimens will specifically target 
aberrations that drive tumor growth and survival. 
Therefore, identifying and administering the appropri-
ate drug based on genetic profiling will improve clini-
cal outcomes and decrease toxicity. We anticipate that 
identification of novel cancer targets will further aid in 
understanding of cancer heterogeneity and in refine-
ment of personalized therapeutic strategies.
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INTRODUCTION
Advances in high-throughput technologies, such as mi-
croarray and next generation sequencing (NGS), have 
led to the discovery of  novel therapeutic targets and 
revealed the power of  predictive and prognostic markers 
in patient care. In addition, such comprehensive genomic 
approaches have increased our understanding of  critical 
cellular and molecular mechanisms of  cancer[1,2]. To date, 
hundreds of  cancer-causing mutations have been discov-
ered by genome-wide sequencing of  the entire exome of  
more than 3000 tumors[3-5]. Most of  the mutated cancer-
causing genes may already have been identified, as the 
more recent NGS studies have reported previously 
identified mutants from different tumor types[5]. Because 
of  this depth of  knowledge regarding cancer genomes, 
we can now target specific aberrations that drive tumor 
growth and survival and customize drug combinations 
for individual patients. Despite the feasibility and clinical 
advantages of  personalized cancer therapy, only a small 
minority of  patients are being tested for biomarkers and 
treated accordingly. Moreover, most emerging drug can-
didates with no predictive biomarkers fail in clinical tri-
als. Therefore, it is essential to determine which specific 
targeted therapies are most efficacious for particular sets 
of  patients, and optimization of  these treatment regi-
mens should be a priority of  future research.
Gastric cancer is one of  the most common malig-
nancies worldwide and is the most frequent cancer diag-
nosed in East Asian countries[6]. Since gastric cancer is 
a heterogeneous disease, both histologically and geneti-
cally, it is difficult to predict patient outcomes using clas-
sical histologic and molecular classifications[7]. Surgery 
is the only curative treatment strategy; yet, even when 
the primary tumor is resected, some early gastric cancer 
patients will ultimately succumb to the disease as a re-
sult of  recurrence of  local or distant tumors. Although 
not necessary in all patients, adjuvant chemotherapy has 
been shown to benefit some patients with early gastric 
cancer, whereas conventional chemotherapy has limited 
efficacy for advanced gastric cancer, with an overall sur-
vival of  approximately ten mo. Therefore, to improve 
prognosis of  these high-risk patients, it is important to 
identify predictive biomarkers and to develop refined 
treatment strategies.
MOLECULAR HETEROGENEITY OF 
GASTRIC CANCER
Human epidermal growth factor receptor 2 (HER2; 
also known as ERBB2) is a receptor associated with cell 
survival, proliferation, migration, adhesion, and differ-
entiation. In the trastuzumab for gastric cancer trial, 594 
patients with gastric cancer with overexpression of  the 
HER2 protein were randomly assigned to two treatment 
groups, chemotherapy (capecitabine/fluorouracil plus 
cisplatin) or chemotherapy in combination with trastu-
zumab (a monoclonal antibody that inhibits HER2)[8]. 
Trastuzumab extended the median overall survival from 
11.1 to 13.8 mo (HR = 0.74; P = 0.0046). This finding 
satisfied the primary objective of  the trial and was later 
referenced in the National Comprehensive Cancer Net-
work guideline.
In addition to the HER2 pathway, there are many 
other pathways abnormally regulated in gastric cancer. 
These include the fibroblast growth factor receptor 
(FGFR) family, the hepatocyte growth factor (HGF)-
mesenchymal epithelial transition factor axis, the phos-
phatidylinositol 3-kinase (PI3K)-AKT-mammalian target 
of  rapamycin (mTOR) factors, and the RAS/RAF/
MEK/mitogen-activated protein kinase factors.
Genetic amplification, translocation or mutation of  
FGFR accelerates growth in a variety of  cancers. More 
specifically, FGFR2 has been reported as amplified in 
9% of  gastric cancer specimens[9]. For the HGF/Met 
pathway, dysregulation can occur by aberrant paracrine 
and autocrine activation via inappropriate ligand pro-
duction, activating mutations, genomic amplification, 
increased transcription, or Met receptor overexpression. 
Overexpression of  Met has been detected in human 
gastric cancers and is associated with a more aggressive 
phenotype[10-12]. Notably, rilotumumab (a monoclonal 
antibody targeting the Met-HGF axis) yielded superior 
overall survival rates in a subgroup analysis of  a phase 
Ⅱ randomized study. Patients with high levels of  Met 
expression were treated with either epirubicin, cisplatin, 
and capecitabine (ECX) in combination with rilotumum-
ab or ECX alone in the first-line setting (11.1 mo vs 5.7 
mo, HR = 0.29; 95%CI: 0.11-0.76, P = 0.012)[13]. Activa-
tion of  the PI3K/Akt/mTOR signaling pathway is cor-
related with poor prognosis and has also been studied as 
a therapeutic target[14,15]. A phase Ⅲ trial that evaluated 
supportive care in combination with either everolimus 
(an inhibitor of  mTOR) or placebo for patients with 
advanced stage gastric cancer yielded negative results, 
where there was no significant difference in overall 
survival between the treatment arms (5.4 mo vs 4.3 mo 
for the everolimus and placebo groups, respectively)[16]. 
Histone deacetylase and poly (ADP-ribose) polymerase 
(PARP; a family of  proteins involved in a number of  cel-
lular processes involving DNA repair and programmed 
cell death) have been investigated as treatment targets 
for gastric cancer[17,18]. Angiogenesis is essential in cancer 
development, growth, and proliferation, and the vas-
cular endothelial growth factor (VEGF) and receptor 
(VEGFR) have been spotlighted as therapeutic targets. 
Recently, the REGARD Trial reported that ramucirumab 
(a VEGFR-2 monoclonal antibody) improved both pro-
gression-free survival and overall survival (vs placebo)[19]. 
Many clinical trials have evaluated molecular targeting 
agents that correspond to the various aforementioned 
signaling pathways (Figure 1), and many of  them are on-
going (Table 1)[8,18-23].
Due to large-scale molecular techniques, our under-
standing of  the molecular complexity underlying gastric 
cancer has increased, and the development of  prognostic 
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Figure 1  Molecular targeting agents for different signaling pathways in gastric cancer. PI3K: Phosphatidylinositol 3-kinase; HER: Human epidermal growth fac-
tor receptor; FGFR: Fibroblast growth factor (FGF) receptor; mTOR: Mammalian target of rapamycin; HGF: Hepatocyte growth factor; VEGFR: Vascular endothelial 
growth factor (VEGF) receptor; EGF: Epidermal growth factor; MAPK: Mitogen-activated protein kinase.
Table 1  Recent phase Ⅲ clinical trials investigating molecular targeting agents in gastric cancer
Clinical trial Biomarker n Results Achievement of primary objective Ref.
HER2 inhibitor
Capecitabine/cisplatin ± trastuzumab (ToGA) HER2 584 PFS 6.7 mo vs 5.5 mo, P = 0.0002 Positive [8]
OS 13.8 mo vs 11.1 mo, P = 0.0046
Capecitabine/oxaliplatin ± lapatinib (LOGiC) HER3 545 Enrollment done NP (NCT00680901)
Paclitaxel ± lapatinib (TYTAN) HER4 261 OS 11.3 mo vs 8.8 mo, P = 0.2088 Negative [20]
EGFR inhibitor
Capecitabine/cisplatin ± cetuximab (EXPAND) NA 904 PFS 5.6 mo vs 4.4 mo, P = 0.3158 Negative [21]
OS 10.7 mo vs 9.4 mo, P = 0.9547
Increased toxicity
Epirubicin/oxaliplatin/capecitabine ± panitu-
mumab (REAL-3)
NA 553 PFS 6.0 mo vs 7.4 mo, P = 0.068 Negative [22]
OS 8.8 mo vs 11.3 mo, P = 0.013
Increased toxicity
Angiogenesis inhibitor
Capecitabine/cisplatin ± bevacizumab (AVA-
GAST)
NA 774 PFS 6.7 mo vs 5.3 mo, P = 0.0037 Negative [23]
OS 12.1 mo vs 10.1 mo, P = 0.1002
Ramucirumab vs placebo (REGARD) NA 355 PFS 2.1 mo vs 1.3 mo, P < 0.0001 Positive [19]
OS 5.2 mo vs 3.8 mo, P = 0.0473
Paclitaxel ± ramucirumab (RAINBOW) NA 665 Enrollment done NP (NCT01170663)
Afatinib vs placebo NA 270 Enrolling NP (NCT01512745)
C-MET/HGF pathway inhibitor
Epirubicin/cisplatin/capecitabine ± rilotumumab 
(RILOMET-1)
MET 450 Enrolling NP (NCT01697072)
Fluorouracil/folinic acid/oxaliplatin ± onartu-
zumab (MetGastric)
MET 800 Enrolling NP (NCT01662869)
HER2
PI3K/Akt/mTOR pathway inhibitor
Everolimus vs placebo NA 648 PFS 1.68 mo vs 1.41 mo, P < 0.00001 Negative [16]
OS 5.39 mo vs 4.34 mo, P = 0.1244
Paclitaxel ± everolimus (AIO-STO-0111) NA 480 Enrolling NP (NCT01248403)
NA: Not applicable; NCT: ClinicalTrials.gov identifier; NP: Not published; OS: Overall survival; PFS: Progression-free survival; PI3K: Phosphatidylinositol 
3-kinase; HER: Human epidermal growth factor receptor; mTOR: Mammalian target of rapamycin.
P P
P P
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classifications based on gene expression profiles is rap-
idly evolving[24-28]. For example, two distinct gastric can-
cer subclasses that were strongly associated by prognosis 
were linked by analyzing gene expression profiles[29]. In-
terestingly, whole exome sequencing of  a gastric adeno-
carcinoma revealed recurrent somatic mutations in both 
cell adhesion and chromatin remodeling genes[30]. The 
characterization of  more molecular processes and inter-
actions will yield effective tailored therapies to improve 
patient outcome and reduce drug toxicity.
GENE EXPRESSION MICROARRAY
A recent study by Ahn et al[29] identified the prognostic 
gene expression signatures of  six genes significantly as-
sociated with survival and relapse and developed a scor-
ing system based on these genes. Specifically, reverse 
transcriptase polymerase chain reaction was performed 
on paraffin-embedded tissues, and microarray was used 
to generate and analyze gene expression profiling data 
from 65 gastric cancer patients. Two distinct subgroups 
were strongly associated with prognosis (Figure 2). The 
C1 subgroup was linked with a poor prognosis, and six 
genes were identified whose expressions were unique 
to this subgroup (CTNNB1, EXOCS3, TOP2A, LBA1, 
CCL5, and LXTR1). Next, a scoring system based on 
the six genes was developed that independently predict-
ed the likelihood of  relapse after curative resection. This 
suggested that the distinct gene expression signature ac-
curately reflected the clinical differences between patient 
subgroups and that such screens can provide informa-
tion on disease trajectory. In the future, the efficacy of  
the risk score will be evaluated as a predictive marker for 
clinical response to adjuvant chemotherapy.
In another study using a gene expression microarray, 
the M2 isoform of  pyruvate kinase (PKM2) was found 
to be overexpressed in gastric cancers at both the mRNA 
and protein levels relative to normal gastric tissues. Its 
expression was negatively correlated with survival in 
signet-ring cell gastric cancer patients. PKM2 expression 
may be an adverse prognostic factor for signet-ring cell 
carcinomas, and the biological role of  PKM2 in gastric 
cancer development and its prognostic value need to be 
further elucidated[31].
MICRORNA MICROARRAY
MicroRNA (miRNA) play a role in the pathogenesis 
of  various human cancers[32]. Although some miRNAs 
have been shown to function as oncogenes and oth-
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Figure 2  Prognostic expression signatures of genes associated with survival. A: Hierarchical clustering of gene expression data from 65 gastric cancer and 6 
gastrointestinal stromal tumors patients in the Yonsei gastric cancer (YGC) cohort; B: Kaplan-Meier plots of 3 gastric cancer clusters in the YGC cohort; C: Kaplan-
Meier plots of stage III patients in 2 clusters (C1 and C2) in the YGC cohort. RFS: Recurrence-free survival.
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ers as tumor suppressors, their mechanisms remain to 
be elucidated[33,34]. The relationship between miRNA 
expression profile and gastric cancer prognosis[35,36] and 
pathogenesis[37,38] has been actively explored. For exam-
ple, miR-196b may be a useful marker, as overexpression 
of  miR-196b has been linked to leukemia and several 
solid cancers, including gastric cancer[39,40]. Whether miR-
196b is an oncogene or tumor suppressor and whether 
it has a role in gastric carcinogenesis and progression 
have not yet been confirmed[41]. Recently, miR-21, miR-
106b, miR-17, miR-18a and miR-20a were identified as 
the five most consistently identified miRNAs in screens 
of  gastric cancer. The association between expression 
level of  these miRNAs and clinicopathological features 
of  gastric cancer was significant, and these miRNAs are 
potential diagnostic and/or prognostic markers that war-
rant further investigation[42].
RNA-sequencing
RNA-sequencing (RNA-seq) technology enables in-
vestigators to simultaneously quantify gene expression 
levels, assess alternative splicing and gene fusion events, 
and detect nucleotide variations in transcribed regions. 
In particular, whole-transcriptome RNA-seq provides a 
detailed view of  the spectrum of  expressed transcripts 
of  both coding and noncoding mRNA[43]. Recently, a 
central metabolic regulator AMP-activated protein kinase 
(AMPK) was identified as a potential functional target in 
Asian gastric cancer. As seen in Figure 3, a simple scor-
ing analysis found that only PRKAA2 (AMPKα2) was 
identified as a potential key modulator of  gastric cancer 
progression. Importantly, the translational relevance 
of  this gene as a target for early-stage gastric cancer 
was suggested by functional studies in gastric cancer 
cell lines[44]. Relative to previous RNA-seq studies, this 
whole-transcriptome RNA-seq approach has several 
advantages. First, two protocols were used that comple-
mentarily covered RNA fragments of  different sizes. In 
this manner, quantification of  mRNA, long noncoding 
RNA and miRNA expression could be conducted si-
multaneously. Second, ribosome-depleted RNA samples, 
rather than poly A-enriched RNA samples, were se-
quenced, thereby generating a less biased population of  
transcribed molecules. Third, strand-specific short reads 
were used, and this allowed for more accurate quantifica-
tion of  gene expression. In the future, further functional 
studies will be necessary to elucidate whether AMPKα2 
is an effective therapeutic target.
CONNECTIVITY MAP
The Connectivity Map is a web-based interface (http://
www.broadinstitue.org/cmap) that contains more than 
7000 expression profiles representing effects of  1309 
compounds on several cultured human cells[45]. Analyses 
using the Connectivity Map reveal functional connec-
tions between drugs, genes, and disease and provide a 
novel approach for cancer treatment. Candidate agents 
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Figure 3  Simple scoring analysis of Asian gastric cancer. Three criteria were used to select key genes: (1) Genes that were identified in both 5-group and 4-stage 
differential expression analysis; (2) Target genes of six key differentially expressed miRNAs, where the target genes were predicted by TargetScan (Rs < -0.4, P < 0.05); 
and (3) Genes with recurrent somatic mutations or their interactors (Ingenuity Pathway Analysis program annotation). Only two genes met two criteria, and PRKAA2 
was the only gene that met all three criteria. miRNA: MicroRNA.
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against a specific disease can be recognized by applying 
disease-specific gene expression profiles to Connectivity 
Map analysis[46]. Recently, a gastric cancer gene signa-
ture was applied to the Connectivity Map, and analysis 
revealed that histone deacetylase inhibitors, including 
vorinostat and trichostatin A, were potential drugs for 
the treatment of  gastric cancer. These findings were 
validated in vitro using gastric cancer cell lines, wherein 
vorinostat significantly inhibited cell viability in a dose-
dependent manner[17]. Therefore, application of  unique 
gene expression profiles to the Connectivity Map may be 
a viable strategy for the discovery of  novel therapeutic 
agents for gastric cancer.
CONCLUSION
Advances in molecular diagnostics rely more on classify-
ing tumors based on the pathways that drive the onco-
genic process, rather than by the tissue of  origin. Such 
molecular tumor classification schemes are very useful 
in selecting the appropriate pathway inhibitor to apply to 
an individual patient. Genomic technologies enable ro-
bust tumor genomic profiling in the clinical arena (Figure 
4) and make it possible to match plausible genetic altera-
tions with rational therapeutic regimens. This means that 
data from cancer genomes may dictate rational treatment 
decisions that are tailored for a specific tumor. Impor-
tantly, the patients benefit from use of  these biomarkers, 
as the most effective therapy would be selected upfront, 
sparing the patient from the considerable toxicity associ-
ated with conventional “trial and error” therapy. How-
ever, the genome era also poses clinical challenges. This 
unprecedented flow of  tumor and germline genomic 
information needs to be supported by clinical-grade data 
interpretation. Oncologists will be required to conduct 
a new generation of  evidence-based clinical trials to ac-
commodate smaller numbers of  patients with discrete 
genetic alterations. To aid in this discovery, platforms 
for repeat biopsy and tissue banking should be estab-
lished. Moreover, the roles of  personalized surgery and 
radiotherapy should not be underestimated. Defining 
a subgroup of  patients who benefit from radiotherapy 
and the potential interactions between patient character-
istics and the efficacy of  radiotherapy should be further 
explored in the future. We believe this confluence of  
science, technology, drug discovery, and clinical trial will 
lead to successful implementation of  informed personal-
ized cancer medicine.
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